GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Geron gave investors the false impression that it had reliable information about its projected revenue outlook and anticipated growth. The Company’s optimistic reports of Rytelo’s launch and potential growth were far too optimistic. The Company failed to inform investors that Rytelo lacked necessary patient awareness for the Company to capitalize on what it had claimed was a significant unmet need for the drug. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Geron, investors suffered damages.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250508333086/en/